Survival Rates2018-12-03T20:16:40+00:00

Patient Survival Rates

Functional Oncology Program Survivor Stats

The patient survival statistics are a small representation of the overall outcomes recorded by patients that underwent at least one of our cancer treatments and have approved our use of their information for statistical record keeping.

These numbers are intended to provide patients a general overlook at possible outcomes per type of condition but it’s important to understand that every patient’s cancer treatment and illness is treated different and can produce very different outcomes based on many aspects that should be discussed individually with your doctor despite our best intention to provide measurable baseline information for the consideration of our program.

Cancer Type Case Number Stage I Stage II Stage III Stage IV Benefit Rate (%)
Lung Cancer 1067 33 97 408 428 90%
Pancreatic Cancer 195 3 11 32 87 93%
Breast Cancer 125 2 3 16 67 88%
Ovarian Cancer 52 0 3 9 28 92%
Colon Cancer 47 0 1 5 28 87%
Lymphoma 40 2 9 8 4 93%
Cervical Cancer 24 1 1 5 12 96%
Bladder Cancer 11 0 1 0 4 100%
Cancer Type Case Number Benefit Rate (%)
Lung Cancer 1067 90%
Pancreatic Cancer 195 93%
Breast Cancer 125 88%
Ovarian Cancer 52 92%
Colon Cancer 47 87%
Lymphoma 40 93%
Cervical Cancer 24 96%
Bladder Cancer 11 100%

“Over 50% of patient survivors are living more than 2 years”

The following information represents the number of months that patients have survived after undergoing at least one of our available cancer treatments.

This includes information sample for cancer patients which have agreed to release information for statistical purposes.

CR= Complete Response | PR= Partial Response | SD=Stable | PD=Progress | Effect rate= CR+PR | Benefit Rate=CR+PR+SD

Cancer Type Case Number Stage I Stage II Stage III Stage IV Not Staged CR PR SD PD Effect Rate Benefit Rate (%) Side Effects
(%)
Lung Cancer 1067 33 97 408 428 101 17 298 642 110 30 90 No except fever
Pancreatic Cancer 195 3 11 32 87 62 0 14 168 13 7 93 No except fever
Breast Cancer 125 2 3 16 67 37 3 33 74 15 29 88 No except fever
Ovarian Cancer 52 0 3 9 28 12 0 12 36 4 23 92 No except fever
Colon Cancer 47 0 1 5 28 13 0 7 34 6 15 87 No except fever
Lymphoma 40 2 9 8 4 17 6 16 15 2 55 93 No except fever
Cervical Cancer 24 1 1 5 12 5 3 3 17 1 25 96 No except fever
Bladder Cancer 11 0 1 0 4 6 0 2 9 0 18 100 No except fever
Esophageal Cancer 1085 10 313 363 341 58 55 242 711 77 27 93 No except fever
Liver Cancer 463 8 96 121 103 135 0 81 351 31 18 93 No except fever
Gastric Cancer 169 6 18 31 86 28 0 27 125 17 16 90 No except fever
Rectal Cancer 133 4 12 8 47 62 0 23 98 12 17 91 No except fever
Cardiac Cancer 110 1 14 32 40 23 2 26 74 8 25 93 No except fever
Kidney Cancer 33 2 0 2 15 14 0 2 26 5 6 85 No except fever
Thyroid Cancer 24 0 2 3 5 14 0 2 18 4 8 83 No except fever
Hypopharyngeal Cancer 21 1 1 5 9 5 0 4 15 2 19 90 No except fever
Nasopharyngeal Cancer 16 0 2 7 3 4 0 3 11 2 19 88 No except fever
Endometrial Cancer 14 0 0 0 9 5 1 3 7 3 29 79 No except fever
Laryngeal Cancer 11 0 0 2 4 5 0 2 7 2 18 82 No except fever
Parotid Gland Cancer 10 0 0 0 5 5 0 3 6 1 30 90 No except fever
Other Cancer 242 1 0 15 53 173 2 44 173 24 19 90 No except fever
Total 3892 74 584 1072 1378 784 89 847 2617 339 24 91

The following information represents the number of months that patients have survived after undergoing at least one of our available cancer treatments.

This includes information sample for cancer patients which have agreed to release information for statistical purposes.

CR= Complete Response | PR= Partial Response | SD=Stable | PD=Progress | Effect rate= CR+PR | Benefit Rate=CR+PR+SD

Cancer Type Case Number Stage I Stage II Stage III Stage IV Not Staged CR PR SD PD Effect Rate Benefit Rate (%) Side Effects
(%)
Lung Cancer 1067 33 97 408 428 101 17 298 642 110 30 90 No except fever
Pancreatic Cancer 195 3 11 32 87 62 0 14 168 13 7 93 No except fever
Breast Cancer 125 2 3 16 67 37 3 33 74 15 29 88 No except fever
Ovarian Cancer 52 0 3 9 28 12 0 12 36 4 23 92 No except fever
Colon Cancer 47 0 1 5 28 13 0 7 34 6 15 87 No except fever
Lymphoma 40 2 9 8 4 17 6 16 15 2 55 93 No except fever
Cervical Cancer 24 1 1 5 12 5 3 3 17 1 25 96 No except fever
Bladder Cancer 11 0 1 0 4 6 0 2 9 0 18 100 No except fever
Esophageal Cancer 1085 10 313 363 341 58 55 242 711 77 27 93 No except fever
Liver Cancer 463 8 96 121 103 135 0 81 351 31 18 93 No except fever
Gastric Cancer 169 6 18 31 86 28 0 27 125 17 16 90 No except fever
Rectal Cancer 133 4 12 8 47 62 0 23 98 12 17 91 No except fever
Cardiac Cancer 110 1 14 32 40 23 2 26 74 8 25 93 No except fever
Kidney Cancer 33 2 0 2 15 14 0 2 26 5 6 85 No except fever
Thyroid Cancer 24 0 2 3 5 14 0 2 18 4 8 83 No except fever
Hypopharyngeal Cancer 21 1 1 5 9 5 0 4 15 2 19 90 No except fever
Nasopharyngeal Cancer 16 0 2 7 3 4 0 3 11 2 19 88 No except fever
Endometrial Cancer 14 0 0 0 9 5 1 3 7 3 29 79 No except fever
Laryngeal Cancer 11 0 0 2 4 5 0 2 7 2 18 82 No except fever
Parotid Gland Cancer 10 0 0 0 5 5 0 3 6 1 30 90 No except fever
Other Cancer 242 1 0 15 53 173 2 44 173 24 19 90 No except fever
Total 3892 74 584 1072 1378 784 89 847 2617 339 24 91

“Over 90% of cancer patients have between 80%-95% benefit rate including stage 4 patients”

The following information has been collected over 20 years to demonstrate the efficacy of our treatments.

Source: (1) “Use of Hapten Combined Cytotoxic Drugs for Enhancing Therapeutic Effect in Advanced Stages of Pancreatic Cancer,” Journal of Liver Research, Disorders & Therapy, December 30, 2015; (2) “Hapten Improved Overall Survival Benefit in Late Stages of Non-Small Cell Lung Cancer (NSCLC) by at least one of our Functional Oncology available treatments (Our Treatments), Therapy With and without Radiation Therapy,” Journal of Cancer Prevention & Current Research, February 8, 2016; (3) Journal of Hepatocellular Carcinoma, 2015:2 1-12. (4) SEER data, based on compiled 2007-2013data

Indication

Survival Rates

Conventional Standard Care Intratumoral Chemoteraphy

Our Treatments
(at least 1 of our treatments)

Advanced Pancreatic Cancer
(120 cases)

6 Month Survival Rate (%)

27%

18%

77%

12 Month Survival Rate (%)

13%

9%

57%

Advanced Lung Cancer
(259 cases)

6 Month Survival Rate (%)

39%

61%

95%

12 Month Survival Rate (%)

23%

33%

86%

2 Year Survival Rate (%)

11%

7%

37%

Liver Cancer
(221 cases)

6 Month Survival Rate (%)

NA

32%

61%

12 Month Survival Rate (%)

17%

19%

30%

The following information has been collected over 20 years to demonstrate the efficacy of our treatments.

Source: (1) “Use of Hapten Combined Cytotoxic Drugs for Enhancing Therapeutic Effect in Advanced Stages of Pancreatic Cancer,” Journal of Liver Research, Disorders & Therapy, December 30, 2015; (2) “Hapten Improved Overall Survival Benefit in Late Stages of Non-Small Cell Lung Cancer (NSCLC) by at least one of our Functional Oncology available treatments (Our Treatments), Therapy With and without Radiation Therapy,” Journal of Cancer Prevention & Current Research, February 8, 2016; (3) Journal of Hepatocellular Carcinoma, 2015:2 1-12. (4) SEER data, based on compiled 2007-2013data

Indication

Survival
Rates

Conventional
Standard
Care

Our
Treatments
(at least 1
of our
treatments)

Advanced
Pancreatic
Cancer
(120 cases)

6 Month
Survival
Rate (%)

27%

77%

12 Month
Survival
Rate (%)

13%

57%

Advanced
Lung
Cancer
(259 cases)

6 Month
Survival
Rate (%)

39%

95%

12 Month
Survival
Rate (%)

23%

86%

2 Year
Survival
Rate (%)

11%

37%

Liver
Cancer
(221 cases)

6 Month
Survival
Rate (%)

NA

61%

12 Month
Survival
Rate (%)

17%

30%

Request More Information